Editas, Adverum extend CRISPR ocular delivery alliance by Nick Paul Taylor Friday, January 26, 2018 The amended agreement gives Editas until the end of September to exercise its option on the first of five ocular indications covered by the contract.
Aerie raids Alcon again, returning this time with an R&D VP by Nick Paul Taylor Tuesday, September 19, 2017 Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.
FDA clears Optovue’s epithelial thickness mapping software by Nick Paul Taylor Wednesday, August 9, 2017 Doctors can use the software and accompanying optical coherence tomography device to automatically assess the thickness of the epithelia and stroma.
Langer’s Kala files for $86M IPO to bring eye drug to market by Nick Paul Taylor Monday, June 26, 2017 Kala Pharmaceuticals has filed to list on Nasdaq to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.
Eye specialist Ocugen looks east for second-round fundraising by Phil Taylor Thursday, June 15, 2017 Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.
Editas delays IND for Allergan-partnered CRISPR program by Nick Paul Taylor Tuesday, May 16, 2017 Editas Medicine has delayed the target date for filing an IND for its lead Allergan-partnered CRISPR program.
Avedro raises $42M, opens plant to step up device rollout by Nick Paul Taylor Friday, April 28, 2017 Avedro has raised $42 million to further commercialization and development of its corneal collagen cross-linking technology.
